系统分析的目的是通过检索PubMed数据库中2019年3月至2022年3月关于益生菌治疗肠易激综合征（IBS）的随机对照试验（RCTs），以评估益生菌对IBS患者的治疗效果。其中符合纳排标准的RCTs共9项，7项（77.78%）研究报告，与安慰剂相比，益生菌可显著改善IBS患者症状(P<0.05)，其余2项（22.22%）没有报告IBS症状的显著缓解。报告有益的7项研究中，4项使用单菌株益生菌，其余3项使用多菌株益生菌。2项研究对IBS亚型进行分析，结果显示益生菌可改善IBS亚型患者的临床症状。总体而言，无论是单菌株还是多菌株益生菌，均可显著改善IBS患者症状，两者疗效无明显差异。

The purpose of this systematic analysis was to evaluate the efficacy of probiotics in patients with irritable bowel syndrome (IBS) by searching the PubMed database of randomized controlled trials (RCTs) on probiotics for IBS from March 2019 to March 2022. A total of 9 RCTs that met the criteria were retrieved. In which,7 studies (77.78%) reported that probiotics significantly improved IBS patients' symptoms compared with placebo (P<0.05), and the remaining 2 studies (22.22%) reported no significant relief of IBS symptoms. Of the seven studies that reported benefit, four used mono-strain probiotic and the remaining three used multi-strain probiotic. Two studies analyzed IBS subtypes and showed that probiotics improved clinical symptoms in patients with IBS subtype. Overall, both single-strain and multi-strain probiotics can significantly improve symptoms in patients with IBS, and there is no significant difference in efficacy between the two.

内蒙古自然科学基金 (2019LH08025); 国家自然科学基金（82260115）